PARP INHIBITORS IN FIRST LINE OVARIAN CANCER TREATMENT: PREDICTION OF RESPONSE AND RESISTANCE
Ente Finanziatore: Ministero della Salute
Principal Investigator: Dott.ssa Mezzanzanica Delia
Data di inizio:
Data di fine:
Struttura Principale: Anatomia Patologica 1
Approximately, 50% of high grade ovarian serous cancer (HGSOC) present Homologus Recombination Deficiency (HRD). Very recently, intriguing clinical data challenged the role of Bevacizumab or PARP inhibitors (PARPi) as first line treatment for these patients.
In particular, the role of HRD in predicting a meaningful benefit from these treatments is unclear. To date, clinicans are facing the conundrum of choosing the right frontline treatment for ovarian cancer patients.
The purpose of this study is to evaluate PFS of patients with newly diagnosed HSGOC who receive the PARPi Rucaparib or bevacizumab or the combination of both with platinum-based chemotherapy. Moreover, the study will address predictive biomarkers of response and resistance to PARPi in tissue and in liquid biopsy.
Principal Investigator Dr. Mezzanzanica Delia
Struttura Principale: Pathological Anatomy 1
Complex Structure
Last update: 02/09/2025